These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28418733)

  • 1. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.
    van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH
    Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pharmacokinetics of 2'-
    Bosgra S; Sipkens J; de Kimpe S; den Besten C; Datson N; van Deutekom J
    Nucleic Acid Ther; 2019 Dec; 29(6):305-322. PubMed ID: 31429628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
    Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
    Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide conjugation of 2'-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice.
    Jirka SM; Heemskerk H; Tanganyika-de Winter CL; Muilwijk D; Pang KH; de Visser PC; Janson A; Karnaoukh TG; Vermue R; 't Hoen PA; van Deutekom JC; Aguilera B; Aartsma-Rus A
    Nucleic Acid Ther; 2014 Feb; 24(1):25-36. PubMed ID: 24320790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies on intestinal administration of antisense oligonucleotides as a model for oral delivery for treatment of duchenne muscular dystrophy.
    van Putten M; Young C; van den Berg S; Pronk A; Hulsker M; Karnaoukh TG; Vermue R; van Dijk KW; de Kimpe S; Aartsma-Rus A
    Mol Ther Nucleic Acids; 2014 Nov; 3(11):e211. PubMed ID: 25405468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides.
    Bremmer-Bout M; Aartsma-Rus A; de Meijer EJ; Kaman WE; Janson AA; Vossen RH; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Mol Ther; 2004 Aug; 10(2):232-40. PubMed ID: 15294170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice.
    Bassi E; Falzarano S; Fabris M; Gualandi F; Merlini L; Vattemi G; Perrone D; Marchesi E; Sabatelli P; Sparnacci K; Laus M; Bonaldo P; Rimessi P; Braghetta P; Ferlini A
    J Biomed Biotechnol; 2012; 2012():897076. PubMed ID: 23091362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
    Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
    Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy.
    't Hoen PA; van der Wees CG; Aartsma-Rus A; Turk R; Goyenvalle A; Danos O; Garcia L; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Pharmacogenomics; 2006 Apr; 7(3):281-97. PubMed ID: 16610940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model.
    Relizani K; Griffith G; Echevarría L; Zarrouki F; Facchinetti P; Vaillend C; Leumann C; Garcia L; Goyenvalle A
    Mol Ther Nucleic Acids; 2017 Sep; 8():144-157. PubMed ID: 28918017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, biodistribution and safety comparison of chemically modified antisense oligonucleotides in the retina.
    Vázquez-Domínguez I; Anido AA; Duijkers L; Hoppenbrouwers T; Hoogendoorn ADM; Koster C; Collin RWJ; Garanto A
    Nucleic Acids Res; 2024 Sep; 52(17):10447-10463. PubMed ID: 39119918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
    Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
    Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated Myotubes In Vitro.
    González-Barriga A; Nillessen B; Kranzen J; van Kessel IDG; Croes HJE; Aguilera B; de Visser PC; Datson NA; Mulders SAM; van Deutekom JCT; Wieringa B; Wansink DG
    Nucleic Acid Ther; 2017 Jun; 27(3):144-158. PubMed ID: 28375678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Application of an Ultrasensitive Hybridization-Based ELISA Method for the Determination of Peptide-Conjugated Phosphorodiamidate Morpholino Oligonucleotides.
    Burki U; Keane J; Blain A; O'Donovan L; Gait MJ; Laval SH; Straub V
    Nucleic Acid Ther; 2015 Oct; 25(5):275-84. PubMed ID: 26176274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.